PhRMA Funnels Millions to Groups Fighting Drug Pricing Reforms
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
Tax documents reveal the group Center Forward received a record $18.8 million in 2021 and spent big to back conservative Democrats who bucked their party on drug pricing reforms.
Leaders of a centrist advocacy group with funding from the pharmaceutical industry founded outlet The Well News and have editorial input on its promoted posts.
The largest drugmakers spent $56 billion more on stock buybacks and dividends than on research and development from 2016 to 2020, according to a new House committee report.
On average, the signers received $93,275 from the pharmaceutical & health products industry in the 2020 cycle, far more than the average for House Democrats of $37,788.
Americans for Prosperity is hitting six key moderate House Democrats with digital ads opposing reintroduced drug pricing measures.
Center Forward, a "dark money" group with major funding from Big Pharma, is running a Facebook ad campaign touting the pharmaceutical industry as its super PAC spends millions to re-elect Blue Dog Democrats.